<DOC>
	<DOCNO>NCT00800917</DOCNO>
	<brief_summary>This trial investigator initiate , open label phase II study , patient recurrent primary GBM consider study . Only patient recurrence Temozolomide VEGF-directed therapy Bevacizumab consider study . Patients receive temsirolimus 25 mg IV 30-60 minute day 1 , 8 , 15 22 bevacizumab 10 mg/kg IV 30-90 minute day 8 22 . Treatment repeat every 28 day maximum 12 course absence disease progression unacceptable toxicity . A safety analysis perform first 10 patient receive minimum 4 cycle ( 8 week ) . The study stop : If DLT observe &gt; 2/10 patient , Occurrence serious adverse event describe SPC agent , If partial remission observe least 1/10 patient</brief_summary>
	<brief_title>A Study Temsirolimus Bevacizumab Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Written inform consent Histological verification primary GBM failure radiotherapy temozolomide ( TMZ ) Previously treat VEGFdirected therapy bevacizumab Previously receive radiotherapy temozolomide More 4 week since follow prior treatment : chemotherapy ( 6 week nitrosoureas mitomycin C ) Radiotherapy nontarget lesion lesion biopsied VEGFdirected therapy ( include bevacizumab ) Investigational agent More 6 month since prior major surgery open biopsy recover ( 6 week require operation recurrent GBM ) No concurrent medication substance know affect potential affect activity pharmacokinetics follow : Temsirolimus Bevacizumab CYP450 isoenzymes ECOG performance status 01 WBC ≥ 3,000 mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin phosphate normal AST ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Urine protein : creatinine ratio &lt; 1.0 OR 24hour urine protein &lt; 1,000 mg Fasting cholesterol &lt; 350 mg/dL ( cholesterol medication allow ) Fasting triglyceride &lt; 400 mg/dL PT INR ≤ 1.5 Hematocrit &lt; 41 % ( male ) &lt; 38 % ( female ) Fertile female must use approved contraceptive ( ppills , IUD , depot injection gestagen , subdermal implantation , hormonal vaginal ring transdermal depot plaster ) , throughout study 3 month discontinuation study drug . Fertile men must use dobbelt barrier method ( preservative sperm inhibit creme ) female partner us mention contraceptive . Fertile male must use preservative . Clinically significant cardiovascular disease , include follow : Cerebrovascular accident within past 6 month Transient ischemic attack within past 6 month Myocardial ischemia within past 6 month Myocardial infarction within past 6 month Other thromboembolic event within past 6 month Unstable angina within past 6 month Uncontrolled hypertension ( i.e. , hypertension despite maximal therapy ) New York Heart Association class IIIV heart disease Congestive heart failure Serious cardiac arrhythmia require medication Clinically significant peripheral vascular disease Uncontrolled intercurrent illness Ongoing active infection One follow within past 6 month Abdominal fistula Gastrointestinal perforation Intraabdominal abscess Serious nonhealing wound , ulcer , bone fracture Psychiatric illness social situation would preclude study compliance Uncontrolled diabetes Hemoglobin A1c &gt; 7 % Concurrent nonstudy relate surgical procedure Concurrent treatment CYP3A4 inducer inhibitor Other concurrent anticancer agent therapies Significant traumatic injury within past 28 day History allergic reaction compound similar chemical biological composition temsirolimus bevacizumab Hypersensitivity Chinese hamster ovary cell product recombinant human antibody ( e.g. , infliximab ) Pregnancy nursing Patients previously intolerant bevacizumab Anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>